Author(s): Sven Gottschling, Homburg/Saar. Therapists are always facing enormous problems when it comes to treating children with life-limiting illnesses and chronic pain, since most medications are not available in usable pediatric versions, not to mention the adverse effects they cause. It is in these cases where cannabinoids have an interesting therapeutic potential. View study
Cannabinoid receptors and the regulation of bone mass. (2007).
Author(s): I Bab and A Zimmer. Recent studies in mice suggest that cannabinoid receptors could be an important objective to consider for the development of cannabinoid drugs to combat osteoporosis and to develop diagnostic measures to identify polymorphisms sensitive to osteoporosis in the CNR2 gene. View study
Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. (2012).
Author(s): M.R. Pazos, V. Cinquina, A. Gómez, R. Layunta, M. Santos, J. Fernández Ruiz, José Martínez Orgado. CBD has been shown to have short-term neuroprotective effects in the immature brain, suggesting that it could be used as a neuroprotective agent for neonatal hypoxiaeischemia. View study
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. (2007).
Author(s): Ronen Durst, Haim Danenberg, Ruth Gallily, Raphael Mechoulam, Keren Meir, Etty Grad, Ronen Beeri, Thea Pugatsch, Elizabet Tarsish, and Chaim Lotan. CBD exhibits antioxidant and anti-inflammatory properties. These data highlight the anti-inflammatory and vascular stabilizing effects of CBD in endotoxic shock and suggest a potential beneficial effect of this natural cannabinoid. View study
Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury. (2013).
Author(s): In-Young Choi, Chung Ju, Angela M. A. Anthony Jalin, Da In Lee, Paul L. Prather, and Won-Ki Kim. Type 2 cortical cannabinoid receptors could serve as potential therapeutic targets to treat cerebral ischemia. The cannabinoid transcaryophyllene protected brain cells from the effects of ischemia in rats. Post-ischemic treatment with transcaryophyllene reduced the size of cerebral infarction and edema, however, the anti-ischemic benefits of transcaryophyllene deserve further exploration. View study
Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. (2015).
Author(s): Sumner Burstein. Until 1963 the structure of the CBD was not completely elucidated, and THC was thought to be the most powerful and active component of cannabis, a belief that was mostly due to its psychoactive effects. Therefore, the therapeutic benefits of CBD were minimized for a long time. This study focuses on the therapeutic and anti-inflammatory benefits of CBD. View study
Cannabinoid Modulation of Neuroinflammatory Disorders. (2011).
Author(s): Viviane M. Saito, Rafael M. Rezende and Antonio L. Teixeira. Due to their peculiar chemistry, cannabinoids have imposed a challenge on researchers. Cannabinoids have so many benefits that even to date it is impossible to prove or discard each one of them. For now, science aims to understand how cannabinoid compounds are associated with neuroinflammation and how cannabis-based medicine can help millions of patients around the world. The development of safe and effective medicines based on cannabis must overcome the risk of adverse effects. View study
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. (2013).
Author(s): M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, C. Guaza. This study results highlight the anti-inflammatory effects of cannabidiol in this viral model of multiple sclerosis and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component. View study
Around‐the‐Clock Oral THC Effects on Sleep in Male Chronic Daily Cannabis Smokers. (2013).
Author(s): David A. Gorelick, Robert S. Goodwin, Eugene Schwilke, Jennifer R. Schroeder, David M. Schwope, Deanna L. Kelly, Pharm, Catherine Ortemann‐Renon, Denis Bonnet, Marilyn A. Huestis. In this study it has been shown that THC could promote sleep, since its clinical use is associated with drowsiness. View study
Modulation of Sleep-Wake Cycles in Mice and Rats with Cannabinoids. (2012).
Author(s): L. Robinson, A. Plano, A. Goonawardena, B. Platt, G. Riedel. The endocannabinoid system is involved in the modulation of sleep. In addition, this study leads to affirm that cannabinoid agonists could be used in order to treat sleep disorders. View study
Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. (1971).
Author(s): D. M. Paton and R. G. Pertwee. Cannabis extract prolonged sleeping time in mice in a thermally neutral environment (30-32′ C) in which hypothermia does not occur. Cannabis extract inhibits microsomal activity of mouse liver, chiefly by virtue of its cannabidiol content. It is probable that cannabis consumption by man could lead to altered disposal of many other drugs, used in medicine or otherwise. View study
The Nonpsychoactive Cannabis Constituent Cannabidiol Is a Wake-Inducing Agent. (2008).
Author(s): Eric Murillo-Rodrıguez Diana Millan-Aldaco and Marcela Palomero-Rivero Raphael Mechoulam Rene Drucker-Colın. The biological actions of CBD in sleep indicate that it is an inducer of the wake that presumably activates the neurons in LH and DRN, since it increases wakefulness and slows down slow wave sleep and REM sleep. View study
The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation. (2011). Author(s): Eric Murillo-Rodríguez1,*, Alwin Poot-Ake1, Oscar Arias-Carrión2, Elda Pacheco-Pantoja1,Alfredo de la Fuente-Ortegón1 and Gloria Arankowsky-Sandoval3. Pharmacological experiments have shown that the administration of endocannabinoids induces cannabimimetic effects, including sleep promotion. View study
Proof of concept trial of dronabinol in obstructive sleep apnea. (2013).
Author(s): Bharati Prasad, Miodrag G. Radulovacki and David W. Carley. Dronabinol has been shown to be safe and well tolerated to treat patients with obstructive sleep apnea and greatly reduces AHI. View study
Proof of concept trial of dronabinol in obstructive sleep apnea. (2013).
Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat. (2014). Author(s): Michael W. Calik, Miodrag Radulovacki, and David W. Carley. Dronabinol stabilizes the respiratory pattern and increases the muscles of the upper respiratory tract acting on the nodose ganglia, which highlights its therapeutic potential for the treatment of obstructive sleep apnea. View study
Intrahippocampal administration of anandamide increases REM sleep. (2010).
Author(s): Pavel Ernesto Rueda-Orozco∗, Edgar Soria-Gómez, Corinne Jennifer Montes-Rodríguez, Marcel Pérez-Morales, Oscar Prospéro-García. Endocannabinoids administered to the hippocampus elicit REM and support previous studies in which chemical stimulation of the limbic areas triggered sleep. View study